Parathyroid hormone analogues for the treatment of osteoporosis
CA 2126299 C · Owner: National Research Council Of Canada · Inventors: Whitfield, James F.; Willick, Gordon E.; Neugebauer, Witold
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Certain analogues of human parathyroid hormone (hPTH) have been found to be effective for the treatment of osteoporosis while showing decreased side effects. Analogues showing this effect include all sequences from hPTH-(1-28)-NH2 to hPTH- (1-31)-NH2 and all sequences from Leu27-hPTH-(1-28)-NH2 to Leu27-hPTH-(1-34)-NH2. Also included are cyclic analogues cyclo(Lys26-Asp30)Leu27-hPTH-(1-34)NH2 and cyclo (Lys27-Asp30)- hPTH-(1-34)-NH2. Analogues in the form of the carboxyl terminal amide are particularly effective.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 20, 1994 and granted December 12, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 20, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 20, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.